Keen Vision 10-Q: Trust Shrinks to $2.2M, Going-Concern Doubt, Nasdaq Delisting Confirmed
KVAUF sits 21% above its 52-week low of $10.01.
Summary
Keen Vision's trust fell to $2.2M from $57.0M after redemptions, leaving a $4.86M working capital deficit and going-concern doubt ahead of the January 27, 2027 deal deadline. The stock was delisted from Nasdaq on August 3, 2026 and the Novoheart merger agreement remains unsigned.
Key Events · Legal and Risk Events · KVAUF
-
Trust Drained by Redemptions
Cash and investments in the trust account fell to $2,227,578 at September 30, 2026 from $57,003,115 at December 31, 2025, after $55,545,013 was withdrawn for share redemptions during the nine months.
-
Going-Concern Doubt Disclosed
The company reported a working capital deficit of $4,863,380 and $8,376 of cash at bank, and said these conditions raise substantial doubt about its ability to continue as a going concern if a business combination is not consummated by January 27, 2027.
-
Nasdaq Delisting Confirmed
Nasdaq suspended and delisted the units, ordinary shares and warrants on August 3, 2026 for non-compliance with the 36-month SPAC rule and minimum 1,100,000 publicly held shares and 400 holder requirements; the securities now trade OTC under KVACF.
-
Novoheart Merger Still Unsigned
The replacement merger agreement with Novoheart Group Limited under the February 26, 2026 LOI II, whose deadline was extended to April 30, 2026, had not been executed as of the report date.
Analysis · KVAUF · Real Estate & Construction
Keen Vision is a shell with almost nothing left. Redemptions drained the trust from $57.0M to $2.2M in nine months, leaving $8,376 of cash at the bank against $4.9M of current liabilities — a $4.86M working capital deficit. Management states the conditions raise substantial doubt about the ability to continue as a going concern if no business combination closes by January 27, 2027. The company was also delisted from Nasdaq on August 3, 2026 for failing the 36-month SPAC deadline and minimum holder thresholds, and now trades OTC as KVACF. The Novoheart replacement merger agreement, due April 30, 2026, still has not been signed. Public shareholders are effectively left with a liquidation claim on roughly $12.60 per share in trust versus a $12.09 market price, and the warrants expire worthless if the deal fails.
How filings like this one have moved
In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, KVAUF was trading at $12.09 on OTC in the Real Estate & Construction sector, with a market capitalization of approximately $55.8M. The 52-week trading range was $10.01 to $17.00. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.